Clinical trials: Non-Infectious Uveitis of the Posterior Segment of the Eye
Non-Infectious Uveitis
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
A study to evaluate the safety and efficacy of an FAI insert for the management of subjects with non-infectious uveitis affecting the posterior segment of the eye.
- Trial name
- FAI (NCT01694186)
- Testing
- FAI insert
- Where
- 34 sites in United States, Germany and 4 more
- Volunteers
- 129 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Posterior Uveitis, Intermediate Uveitis
Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis
Phase 3, multi-center, randomized, masked, controlled study to evaluate the safety and efficacy of an injectable fluocinolone acetonide intravitreal (FAI) insert for the management of subjects with chronic non-infectious uveitis…
- Conditions
- Posterior Uveitis, Intermediate Uveitis, Panuveitis
- Trial name
- NCT02746991
- Testing
- FAI Insert
- Where
- 15 sites in India
- Volunteers
- 153 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Uveitis; Posterior, Disorder
Study Assessing Double-masked Uveitis Treatment
The purpose of this study is to evaluate the safety and efficacy of intravitreal injections of DE-109 ophthalmic solution.
- Trial name
- SAKURA (NCT01358266)
- Testing
- DE-109 44 ug, DE-109 440 ug, DE-109 880 ug
- Where
- 151 sites in United States, Argentina and 15 more
- Volunteers
- 592 people
- Sponsor
- Santen Inc.
Non-Infectious Uveitis of the Posterior Segment of the Eye
A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program
The objective of this extension study is to evaluate the long-term safety of treatment with DE-109 (440 μg) in subjects with non-infectious uveitis of the posterior segment of the eye who have participated in the SAKURA…
- Trial name
- SPRING (NCT02251938)
- Testing
- DE-109 440 μg
- Where
- 25 sites in United States, Austria and 4 more
- Volunteers
- 60 people
- Sponsor
- Santen Inc.
Uveitis
Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment
The purpose of this study is to collect data on patients with severe uveitis that have required re-implantation of the sustained-release fluocinolone drug delivery device due to depletion of study drug in their previous implanted…
- Trial name
- NCT00543296
- Testing
- 0.59 mg Fluocinolone Acetonide implant
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Duke University
Uveitis, Uveitis, Posterior
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert
A study to evaluate the safety and efficacy of a fluocinolone acetonide intravitreal (FAI) insert in the management of subjects with chronic non-infectious uveitis affecting the posterior segment of the eye.
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Intermediate
- Trial name
- NCT05070728
- Testing
- FAI Insert
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Non Infectious Uveitis
LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
This is a Phase III study to assess the efficacy and safety of DE-109 440 µg every 2 months in subjects with active, non-infectious uveitis of the posterior segment of the eye (NIU-PS).
- Trial name
- NCT03711929
- Testing
- DE-109 Intravitreal Injections, DE-109 Intravitreal Injections (Open Label)
- Where
- 65 sites in United States, Argentina and 2 more
- Volunteers
- 145 people
- Sponsor
- Santen Inc.
Non-Infectious Uveitis
Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis
This trial is a 12 month, Phase 3, multi-center, randomized, single-masked (subject), controlled study designed to evaluate the utilization and safety of the Mk II inserter and the safety of the FAI insert, in subjects with…
- Trial name
- MkII (NCT02748512)
- Testing
- FAI Insert administered using the Mk II inserter, FAI Insert administered using the Mk I inserter
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.